Oxford Biomedica PLC PDMR Dealings (8078E)
2023年7月4日 - 12:31AM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMOXB
RNS Number : 8078E
Oxford Biomedica PLC
03 July 2023
PDMR Dealings
Oxford, UK - 3 July 2023: Oxford Biomedica plc ("Oxford
Biomedica" or " the Company") (LSE:OXB), a quality and
innovation-led viral vector CDMO, today announces that
Non-Executive Directors Dr. Michael Hayden, Dr Heather Preston and
Catherine Moukheibir have purchased ordinary shares in the Company
pursuant to a trading plan put in place on 7 October 2022.
By way of background, and as stated in the Oxford Biomedica 2021
Remuneration Policy which was approved at the 2021 Annual General
Meeting, an additional fee of up to GBP50,000 per annum may be paid
to any Non-Executive Director recruited from or based outside of
the UK to reflect market levels of remuneration for Non-Executive
Directors not based in the UK, subject to their agreement that the
after tax amount of this additional fee will be used to acquire
Oxford Biomedica shares at market value, which must be retained for
at least 12 months from acquisition. The ordinary shares were all
purchased at 430p and the number of ordinary shares purchased along
with further information is set out in the table below:
Name of PDMR Number of Number of ordinary T otal number of
o rdinary shares now held ordinary shares
shares purchased held as a percentage
of the Company's
share capital
Dr. M ichael Hayden 6,684 17,973 0.019
------------------ ------------------- ----------------------
Dr. Heather Preston 6,684 18,298 0.019
------------------ ------------------- ----------------------
C athrine Moukheibir 6,684 18,530 0.019
------------------ ------------------- ----------------------
The below notifications, made in accordance with the
requirements of the EU Market Abuse Regulation, give further
details of the number of ordinary shares purchased.
1. Details of the Person Discharging Managerial Responsibility
("PDMR")
a) Name Dr. Michael Hayden
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Non-Executive Director
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument
ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------
b) Nature of the P urchase of shares
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP4.30 6,684
----------
----------------------------- -----------------------------------
e) Aggregated information
* Aggregate volume 6,684
GBP28,741.20
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2023-07-03
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")
a) Name Dr. Heather Preston
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Non-Executive Director
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument
ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------
b) Nature of the P urchase of shares
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP4.30 6,684
----------
----------------------------- -----------------------------------
e) Aggregated information
* Aggregate volume 6,684
GBP28,741.20
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2023-07-03
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")
a) Name Catherine Moukheibir
----------------------------- -----------------------------------
2. Reason for the notification
------------------------------------------------------------------
a) Position/status Non-Executive Director
----------------------------- -----------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------
3. Details of the Issuer
------------------------------------------------------------------
a) Name Oxford Biomedica plc
----------------------------- -----------------------------------
b) LEI code 213800S1GVQNXQ15K851
----------------------------- -----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
------------------------------------------------------------------
a) Description of Ordinary Shares of 50 pence each
the financial
instrument
ISIN: GB00BDFBVT43
Identification
code
----------------------------- -----------------------------------
b) Nature of the P urchase of shares
transaction
----------------------------- -----------------------------------
c) Currency GBP - British pound
----------------------------- -----------------------------------
d) Price(s) and volumes(s) Price(s) Volume(s)
GBP4.30 6,684
----------
----------------------------- -----------------------------------
e) Aggregated information
* Aggregate volume 6,684
GBP28,741.20
* Aggregated total
----------------------------- -----------------------------------
f) Date of the transaction 2023-07-03
----------------------------- -----------------------------------
g) Place of the transaction London Stock Exchange, Main Market
(XLON)
----------------------------- -----------------------------------
-Ends-
For further information, please
contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led
viral vector CDMO with a mission to enable its clients to deliver
life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the
Company has more than 25 years of experience in viral vectors; the
driving force behind the majority of gene therapies. The Company
collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV) and adenoviral vectors. Oxford
Biomedica's world-class capabilities span from early-stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in
Oxford, UK. It has locations across Oxfordshire, UK and a US-based
subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US.
Learn more at www.oxb.com , www.oxbsolutions.com , and follow us on
LinkedIn , Twitter and YouTube .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFFEDEIVIIV
(END) Dow Jones Newswires
July 03, 2023 11:31 ET (15:31 GMT)
Oxford Biomedica (AQSE:OXB.GB)
過去 株価チャート
から 4 2024 まで 5 2024
Oxford Biomedica (AQSE:OXB.GB)
過去 株価チャート
から 5 2023 まで 5 2024
